• 中药标准品生产商,产品定制服务
  • 去氧紫草素

    Deoxyshikonin

    去氧紫草素
    产品编号 CFN92024
    CAS编号 43043-74-9
    分子式 = 分子量 C16H16O4 = 272.3
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Quinones
    植物来源 The roots of Lithosperraum erythrorhizon Sieb. et Zucc.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    去氧紫草素 CFN92024 43043-74-9 10mg QQ客服:3257982914
    去氧紫草素 CFN92024 43043-74-9 20mg QQ客服:3257982914
    去氧紫草素 CFN92024 43043-74-9 50mg QQ客服:3257982914
    去氧紫草素 CFN92024 43043-74-9 100mg QQ客服:3257982914
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Univerzita Karlova v Praze (Czech Republic)
  • Florida A&M University (USA)
  • Institute of Pathophysiology Medical University of Vienna (Austria)
  • Melbourne University (Australia)
  • Kyoto University (Japan)
  • Leibniz Institute of Plant Biochemistry (Germany)
  • University of Vigo (Spain)
  • University of Bonn (Germany)
  • University of Oslo (Norway)
  • National Research Council of Canada (Canada)
  • Universidade da Beira Interior (Germany)
  • University of Hawaii Cancer Center (USA)
  • Sri Sai Aditya Institute of Pharmaceutical Sciences and Research (India)
  • Universit?t Basel (Switzerland)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Onco Targets Ther.2017, 10:3467-3474
  • Int J Mol Sci.2017, 19(1)
  • J Ethnopharmacol.2017, 198:91-97
  • Evid Based Complement Alternat Med.2017, 2017:7383104
  • Sci Rep. 2018, 10590
  • Int J Mol Sci.2018, 19(9):E2825
  • Molecules.2018, 23(7):E1659
  • South African J of Plant&Soil2018, 29-32
  • BMB Rep.2018, 51(5):249-254
  • Pharmacol Rep.2018, 70(6):1195-1201
  • Sci Rep.2018, 8(1)
  • Planta Med.2018, 84(6-07):465-474
  • Front Neurosci.2019, 13:1091
  • ACS Chem Biol.2019, 14(5):873-881
  • Int J Mol Sci.2019, 20(9):E2244
  • J Ethnopharmacol.2019, 244:112074
  • Int J Immunopathol Pharmacol.2019, 33:2058738419857537
  • Anal Sci.2019, 35(12):1317-1325
  • J Asian Nat Prod Res.2019, 5:1-17
  • Cell Physiol Biochem.2019, 52(6):1255-1266
  • Toxicol In Vitro.2019, 59:161-178
  • Process Biochemistry2019, 87:213-220
  • TCI CO.2019, US20190151281A1
  • ...
  • 生物活性
    Description: Deoxyshikonin and dodecyl gallate show significantly synergic antimicrobial activity with penicillin in vivo and in vitro, and can effectively reduce nasopharyngeal and lung colonization caused by different penicillin-resistant pneumococcal serotypes. Deoxyshikonin exerts very good radical scavenging activities toward ABTS+ but shows moderate inhibition of DPPH·, and shows cytotoxic activities. Deoxyshikonin may be a new drug candidate for wound healing and treatment of lymphatic diseases.
    Targets: VEGFR | HIF | ERK | p38MAPK | Antifection
    In vitro:
    Evid Based Complement Alternat Med. 2013;2013:148297.
    Enhancement of Lymphangiogenesis In Vitro via the Regulations of HIF-1α Expression and Nuclear Translocation by Deoxyshikonin.[Pubmed: 23737816]
    The objectives of this study were to determine the effects of deoxyshikonin on lymphangiogenesis.
    METHODS AND RESULTS:
    Deoxyshikonin enhanced the ability of human dermal lymphatic microvascular endothelial cells (HMVEC-dLy) to undergo time-dependent in vitro cord formation. Interestingly, an opposite result was observed in cells treated with shikonin. The increased cord formation ability following deoxyshikonin treatment correlated with increased VEGF-C mRNA expression to higher levels than seen for VEGF-A and VEGF-D mRNA expression. We also found that deoxyshikonin regulated cord formation of HMVEC-dLy by increasing the HIF-1 α mRNA level, HIF-1 α protein level, and the accumulation of HIF-1 α in the nucleus. Knockdown of the HIF-1 α gene by transfection with siHIF-1 α decreased VEGF-C mRNA expression and cord formation ability in HMVEC-dLy. Deoxyshikonin treatment could not recover VEGF-C mRNA expression and cord formation ability in HIF-1 α knockdown cells. This indicated that deoxyshikonin induction of VEGF-C mRNA expression and cord formation in HMVEC-dLy on Matrigel occurred mainly via HIF-1 α regulation. We also found that deoxyshikonin promoted wound healing in vitro by the induction of HMVEC-dLy migration into the wound gap. This study describes a new effect of deoxyshikonin, namely, the promotion of cord formation by human endothelial cells via the regulation of HIF-1 α .
    CONCLUSIONS:
    The findings suggest that deoxyshikonin may be a new drug candidate for wound healing and treatment of lymphatic diseases.
    Front Microbiol. 2015 May 20;6:479.
    Antibacterial effects of Traditional Chinese Medicine monomers against Streptococcus pneumoniae via inhibiting pneumococcal histidine kinase (VicK).[Pubmed: 26042111]
    Two-component systems (TCSs) have the potential to be an effective target of the antimicrobials, and thus received much attention in recent years. VicK/VicR is one of TCSs in Streptococcus pneumoniae (S. pneumoniae), which is essential for pneumococcal survival. We have previously obtained several Traditional Chinese Medicine monomers using a computer-based screening.
    METHODS AND RESULTS:
    In this study, either alone or in combination with penicillin, their antimicrobial activities were evaluated based on in vivo and in vitro assays. The results showed that the MICs of 5'-(Methylthio)-5'-deoxyadenosine, octanal 2, 4-dinitrophenylhydrazone, deoxyshikonin, kavahin, and dodecyl gallate against S. pneumoniae were 37.1, 38.5, 17, 68.5, and 21 μg/mL, respectively. Time-killing assays showed that these compounds elicited bactericidal effects against S. pneumoniae D39 strain, which led to a 6-log reduction in CFU after exposure to compounds at four times of the MIC for 24 h. The five compounds inhibited the growth of Streptococcus pyogenes, Streptococcus mitis, Streptococcus mutans or Streptococcus pseudopneumoniae, meanwhile, deoxyshikonin and dodecyl gallate displayed strong inhibitory activities against Staphylococcus aureus. These compounds showed no obvious cytotoxicity effects on Vero cells. Survival time of the mice infected by S. pneumoniae strains was prolonged by the treatment with the compounds. Importantly, all of the five compounds exerted antimicrobial effects against multidrug-resistant clinical strains of S. pneumoniae. Moreover, even at sub-MIC concentration, they inhibited cell division and biofilm formation. The five compounds all have enhancement effect on penicillin. Deoxyshikonin and dodecyl gallate showed significantly synergic antimicrobial activity with penicillin in vivo and in vitro, and effectively reduced nasopharyngeal and lung colonization caused by different penicillin-resistant pneumococcal serotypes. In addition, the two compounds also showed synergic antimicrobial activity with erythromycin and tetracycline.
    CONCLUSIONS:
    Taken together, our results suggest that these novel VicK inhibitors may be promising compounds against the pneumococcus, including penicillin-resistant strains.
    Food Chemistry, 2008 , 106 (1) :2-10.
    Antioxidants from a Chinese medicinal herb - Lithospermum erythrorhizon[Reference: WebLink]
    Seven compounds, Deoxyshikonin (1), β,β-dimethylacrylshikonin (2), isobutylshikonin (3), shikonin (4), 5,8-dihydroxy-2-(1-methoxy-4-methyl-3-pentenyl)-1,4-naphthalenedione (5), β-sitosterol (6) and a mixture of two caffeic acid esters [7 (7a,7b)] were isolated from Lithospermum erythrorhizon Sieb et. Zucc. and identified by spectroscopic methods. Among them, compound 5 was isolated from this plant species for the first time.
    METHODS AND RESULTS:
    The antioxidant activities of the seven compounds were compared and evaluated through Rancimat method, reducing power and radical scavenging activity. Results showed that, except compound 6, another 6 compounds all exhibited obvious antioxidant activities against four different methods. Compounds 4 and 7 exerted much more potent antioxidant effects on retarding the lard oxidation than that of BHT and both were found to exhibit strong reducing power. Their antioxidant activities, assessed by Rancimat method and reducing power, decreased in the following order, respectively: compound 7 > 4 > BHT > 2 > 3 > 5 > 1 > 6 and compound 7 > BHT > 4 > 2 approximately 3 approximately 5 > 1> 6. In addition, compounds 1-5 all exerted very good radical scavenging activities toward ABTS+ but showed moderate inhibition of DPPH·, while compound 7 presented as a powerful radical scavenger against both ABTS·+ and DPPH·.
    CONCLUSIONS:
    Thus, our results suggested that L. erythrorhizon could be a promising rich source of natural antioxidants.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.6724 mL 18.3621 mL 36.7242 mL 73.4484 mL 91.8105 mL
    5 mM 0.7345 mL 3.6724 mL 7.3448 mL 14.6897 mL 18.3621 mL
    10 mM 0.3672 mL 1.8362 mL 3.6724 mL 7.3448 mL 9.1811 mL
    50 mM 0.0734 mL 0.3672 mL 0.7345 mL 1.469 mL 1.8362 mL
    100 mM 0.0367 mL 0.1836 mL 0.3672 mL 0.7345 mL 0.9181 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    乙酰氧基异戊酰阿卡宁; Acetoxyisovalerylalkannin CFN92025 69091-17-4 C23H26O8 = 430.5 20mg QQ客服:2159513211
    黄钟花醌; Lapachol CFN97403 84-79-7 C15H14O3 = 242.3 20mg QQ客服:2159513211
    去氧紫草素; Deoxyshikonin CFN92024 43043-74-9 C16H16O4 = 272.3 20mg QQ客服:2932563308
    紫草素; Shikonine CFN92622 517-89-5 C16H16O5 = 288.3 20mg QQ客服:1413575084
    紫草素; Shikonin CFN99907 517-88-4 C16H16O5 = 288.31 20mg QQ客服:1413575084
    乙酰紫草素; Acetylshikonin CFN90308 54984-93-9 C18H18O6 = 330.33 20mg QQ客服:2932563308
    异丁酰紫草; Isobutylshikonin CFN92023 52438-12-7 C20H22O6 = 358.4 10mg QQ客服:215959384
    β,β-二甲基丙烯酰紫草素; Dimethylacrylshikonin CFN90164 24502-79-2 C21H22O6 = 370.39 20mg QQ客服:1148253675
    β,β-二甲基丙烯酰阿卡宁; Beta,beta-Dimethylacrylalkannin CFN90626 34539-65-6 C21H22O6 = 370.4 20mg QQ客服:1413575084
    异戊酰紫草素; Isovalerylshikonin CFN95222 52387-14-1 C21H24O6 = 372.4 10mg QQ客服:1413575084

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产